-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of adidas AG (ADDYY, ADDDF) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of adidas AG (“adidas” or the “Company”) (OTC: ADDYY, ADDDF) investors concerning the Company’s possible violations of federal securities laws.

On November 27, 2022, The Wall Street Journal reported that adidas’s senior leadership had discussed the risks of continuing a relationship with Kanye West as far back as 2018. On this news, ADDDY fell $2.02, or 3.1%, to close at $62.34 per share, while ADDDF fell $0.81, or 1%, to close at $126.44 per share on November 28, 2022, thereby injuring investors.

Then, on February 9, 2023, adidas stated that it expected sales to fall at a high single-digit rate in currency-neutral terms because of the “significant adverse impact of not selling the existing stock” of Yeezy products and that failure to sell the stock of Yeezy would lower Company revenue by 1.2 billion euros (or about $1.29 billion), and operating profit by 500 million euros. On this news, ADDYY fell $7.40, or 9%, to close at $75.16, while ADDDF fell $21.83, or 13.2%, to close at $143.23 per share on February 9, 2023.

Then, on February 21, 2023, S&P Global announced that it was downgrading adidas in part because of the impact of adidas terminating its relationship with Kanye West. On this news, ADDDY fell $3.56, or 4.6%, to close at $73.59, while ADDDF fell $4.85, or 3.2%, thereby injuring investors further.

If you purchased adidas securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

OTCBB:ADDYY

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Law Offices of Howard G. Smith Encourages Lufax Holding Ltd. (LU) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Lufax Holding Ltd. (“Lufax” or the “Company”) (NYSE: LU) securities between April 7, 2023 and January 26, 2025, inclusive (the “Class Period”). Lufax investors have until May 20, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LUFAX HOLDING LTD. (LU), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE...

Law Offices of Howard G. Smith Encourages Gemini Space Station, Inc. (GEMI) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ: GEMI) investors who purchased Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about September 12, 2025 (the “IPO” or “Offering”) and/or securities between September 12, 2025 and February 17, 2026, inclu...

Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”). Atara investors have until May 22, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATARA BIOTHERAPEUTICS, INC. (ATRA), CONTACT THE LAW OFFICES OF HOWARD G. S...
Back to Newsroom